Description

[D-p-Cl-Phe6,Leu17]-VIP TFA is a competitive and selective antagonist of vasoactive intestinal peptide (VIP) receptor, with the IC50 of 125.8 nM. [D-p-Cl-Phe6,Leu17]-VIP TFA has no activity on glucagon, secretin or GRF receptors[1][2][3].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–COVID-19-immunoregulation–C150H240F3ClN44O44—-[1]Pozo D, et, al. Characterization of VIP receptor-effector system antagonists in rat and mouse peritoneal macrophages. Eur J Pharmacol. 1997 Mar 5; 321(3): 379-86.|[2]Pandol SJ, et, al. Vasoactive intestinal peptide receptor antagonist [4Cl-D-Phe6, Leu17] VIP. Am J Physiol. 1986 Apr; 250 (4 Pt 1): G553-7.|[3]Messmer B, et, al. Regulation of exocrine pancreatic secretion by cerebral TRH and CGRP: role of VIP, muscarinic, and adrenergic pathways. Am J Physiol. 1993 Feb; 264(2 Pt 1): G237-42.—-3456.22–98.81–OC(C(F)(F)F)=O.OC(C=C1)=CC=C1C[C@@H](C(N[C@@H](CC(C)C)C(N[C@@H](CC(N)=O)C(N[C@@H](CO)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC(C)C)C(N[C@H](C(N)=O)CC(N)=O)=O)=O)=O)=O)=O)=O)NC([C@H](CCCCN)NC([C@H](CCCCN)NC([C@H](C(C)C)NC([C@H](C)NC([C@H](CC(C)C)NC([C@H](CCC(N)=O)NC([C@H](CCCCN)NC([C@H](CCCNC(N)=N)NC([C@H](CC(C)C)NC([C@H](CCCNC(N)=N)NC([C@H]([C@H](O)C)NC([C@@H](NC([C@H](CC(N)=O)NC([C@H](CC(O)=O)NC([C@H]([C@H](O)C)NC([C@H](NC([C@H](C(C)C)NC([C@H](C)NC([C@H](CC(O)=O)NC([C@H](CO)NC([C@@H](N)CC2=CN=CN2)=O)=O)=O)=O)=O)CC3=CC=C(C=C3)Cl)=O)=O)=O)=O)CC4=CC=C(C=C4)O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O–Inflammation/Immunology; Neurological Disease–DMSO : 100 mg/mL (ultrasonic)–Others—-Others–Peptides